Team:EPF-Lausanne/Safety

From 2011.igem.org

(Difference between revisions)
Line 5: Line 5:
a. Risks to the safety and health of team members or others in the lab?
a. Risks to the safety and health of team members or others in the lab?
-
The aim of our project is to create variants of the TetR transcription factor and to test their binding affinities to E. coli plasmid DNA. Since the nucleotide mutations that are needed to construct these variants are minimal, localized, and well-characterized in literature, there is very little risk of producing dangerous strains of E. coli that might endanger the health and safety of our team and lab members. Nevertheless, a great deal of emphasis is placed within the lab on the proper treatment and disposal of bacteria. Both for the experiment's own success and for the safety of others, all bacterial manipulations (cell cultures, glycerol stocks, mini-preps) that involve exposing bacteria to the air of the lab require the use of a Bunsen burner. Moreover, disposing of all bacteria is a two-step process. First, one must bleach the receptacle containing the bacteria (fill its contents with bleach) under the fume hood. The bleached mixture is then poured into a special canister which is treated separately. Second, all cell pellets or dry receptacles containing or having contained cells must be placed in a special biowaste bag, clearly labelled for that specific use. This bag is then disposed of, every week, by a special team from the Life Sciences building. These precautions, coupled with the usual wearing of nitrile and latex gloves at all times, are adequate to the task of maintaining the safety and health of our iGEM team.  
+
Our project involves the use of E.coli strains that have been used by countless generations of biology researchers without the slightest incident. No health risks are involved. Both for the experiment's own success and for the safety of others, all bacterial manipulations (cell cultures, glycerol stocks, mini-preps) that involve exposing bacteria to the air of the lab require the use of a Bunsen burner. Moreover, disposing of all bacteria is a two-step process. First, one must bleach the receptacle containing the bacteria (fill its contents with bleach) under the fume hood. The bleached mixture is then poured into a special canister which is treated separately. Second, all cell pellets or dry receptacles containing or having contained cells must be placed in a special biowaste bag, clearly labelled for that specific use. This bag is then disposed of, every week, by a special team from the Life Sciences building. These precautions, coupled with the usual wearing of nitrile and latex gloves at all times, are adequate to the task of maintaining the safety and health of our iGEM team.  
b. Risks to the safety and health of the general public if released by design or accident?
b. Risks to the safety and health of the general public if released by design or accident?
-
The accidental or intentional release of any product derived from our iGEM work is highly unlikely to induce any kind of risk whatsoever. The E. coli strain being manipulated in the lab, the DH5-alpha strain, is entirely innocuous. Furthermore, after any of our manipulations, this strain will only bear resistance to at most one antibiotic at any time (from chloramphenicol, kanamycin, or ampicillin). While the intentional release of such a strain is an unfortunate possibility, one must recall that hundreds of these harmless E. coli strains are circulating in the average healthy human's intestine at any given time, and that only a handful of existing strains are known to cause severe damage to human health. Since our lab does not use these strains, the risk to the public is minimal.   
+
There is no risk to the public if these bacteria are ever released into the public.   
c. Risks to environmental quality if released by design or accident?
c. Risks to environmental quality if released by design or accident?
-
No known environmental damages have ever been attributed to the DH5-alpha strain.  
+
No known environmental damages have ever been attributed to the innocuous strains used in our lab.  
Line 50: Line 50:
Switzerland signed the [http://bch.cbd.int/protocol Cartagena Protocol for Biosafety] in 2000, and it was first enforced in 2005. For more information on the Swiss role in the Cartagena protocol, click [http://www.bafu.admin.ch/biotechnologie/01773/01774/index.html?lang=en#sprungmarke3_5 here].  
Switzerland signed the [http://bch.cbd.int/protocol Cartagena Protocol for Biosafety] in 2000, and it was first enforced in 2005. For more information on the Swiss role in the Cartagena protocol, click [http://www.bafu.admin.ch/biotechnologie/01773/01774/index.html?lang=en#sprungmarke3_5 here].  
 +
 +
 +
== Interview with Dr. Stéphane Karlen, Biosafety Coordinator at the EPFL ==
 +
{{:Team:EPF-Lausanne/Templates/Footer}}
{{:Team:EPF-Lausanne/Templates/Footer}}

Revision as of 09:21, 30 August 2011